NASDAQ:HUGE FSD Pharma (HUGE) Stock Forecast, Price & News $1.21 +0.02 (+1.68%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.19▼$1.2250-Day Range$1.07▼$1.6052-Week Range$0.62▼$2.10Volume69,424 shsAverage Volume293,023 shsMarket Capitalization$47.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About FSD Pharma (NASDAQ:HUGE) StockFSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.Read More HUGE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUGE Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin HarringtonSeptember 13, 2023 | finance.yahoo.comFSD Pharma Announces Analyst Coverage Initiated by Singular ResearchOctober 1, 2023 | Stansberry Research (Ad)Experts: NVIDIA Now "Too Big to Succeed"Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.August 25, 2023 | finance.yahoo.comFSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)August 2, 2023 | msn.comFSD Pharma signs licensing deal for alcohol detox drink UnbuzzdJuly 10, 2023 | msn.comFSD Pharma hires legal team to investigate suspected illegal tradingJuly 10, 2023 | finance.yahoo.comFSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stockJuly 4, 2023 | finance.yahoo.comFSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of DirectorsOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.June 30, 2023 | finance.yahoo.comFSD Pharma Inc. Announces Results of Annual General and Special Meeting of ShareholdersJune 21, 2023 | bizjournals.comFormer FSD Pharma CEO Raza Bokhari back in court seeking $30.2M from former employerJune 21, 2023 | finance.yahoo.comDR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLIONMay 16, 2023 | bizjournals.comFormer pharma CEO ordered to pay former employer $2M for arbitration costsMay 16, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration SettlementMay 12, 2023 | finance.yahoo.comFSD Pharma Announces Receipt of Court Action and Update on Spin-Out and DistributionMay 8, 2023 | finance.yahoo.comFSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11May 5, 2023 | markets.businessinsider.comLawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret MisappropriationApril 17, 2023 | finance.yahoo.comGBB Drink Lab Sends a Cease-and-Desist DemandApril 17, 2023 | msn.comNovel Compound Begins Clinical Testing For Potential Treatment Of Multiple SclerosisApril 17, 2023 | finance.yahoo.comFSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple SclerosisApril 12, 2023 | msn.comFSD Pharma To Spin Out New Publicly Trading Subsidiary As Distribution To ShareholdersMarch 31, 2023 | finance.yahoo.comFSD Pharma Announces Filing of Year-End 2022 ResultsMarch 30, 2023 | finance.yahoo.comFSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of AdvisorsMarch 22, 2023 | marketwatch.comFSD Pharma Gets Green Light for Depression-Drug Clinical Trial in AustraliaMarch 22, 2023 | finance.yahoo.comFSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive DisorderMarch 14, 2023 | msn.comPsychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its StockMarch 14, 2023 | finance.yahoo.comFSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its StockSee More Headlines Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE Company Calendar Last Earnings7/20/2023Today10/01/2023Next Earnings (Estimated)11/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HUGE CUSIPN/A CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.46% Return on Assets-86.47% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book1.53Miscellaneous Outstanding Shares39,040,000Free Float35,711,000Market Cap$47.26 million OptionableOptionable Beta0.61 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Zeeshan Saeed (Age 53)Founder, CEO, Pres & Exec. Co-Chairman Comp: $375.98kMr. Anthony John Durkacz (Age 47)Founder & Exec. Co-Chairman Comp: $375.98kMr. Nathan Coyle CPA (Age 42)Chief Financial Officer Comp: $191.89kMr. Donal Carroll CPA (Age 46)Chief Operating Officer Comp: $375.98kDr. Lakshmi P. Kotra BPHARM (Age 52)Ph.D., CEO of Lucid & Director Comp: $331.51kDr. Andrzej Chruscinski M.D.Ph.D., VP of Clinical & Scientific Affairs of LucidMr. Kevin CassidyVP of Quality-LucidMs. Maryann AdessoCorp. Sec.Randell MackPres of FSD BioSciencesMore ExecutivesKey CompetitorsAssembly BiosciencesNASDAQ:ASMBSol-Gel TechnologiesNASDAQ:SLGLLongeveronNASDAQ:LGVNCelularityNASDAQ:CELUvTv TherapeuticsNASDAQ:VTVTView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 1,800 shares on 8/15/2023Ownership: 0.000%Renaissance Technologies LLCBought 33,600 shares on 8/11/2023Ownership: 0.263%AdvisorShares Investments LLCSold 33,074 shares on 8/9/2023Ownership: 0.639%View All Institutional Transactions HUGE Stock - Frequently Asked Questions How have HUGE shares performed in 2023? FSD Pharma's stock was trading at $0.7884 at the start of the year. Since then, HUGE shares have increased by 53.6% and is now trading at $1.2106. View the best growth stocks for 2023 here. When is FSD Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 10th 2023. View our HUGE earnings forecast. How were FSD Pharma's earnings last quarter? FSD Pharma Inc. (NASDAQ:HUGE) issued its earnings results on Thursday, July, 20th. The company reported ($0.14) EPS for the quarter. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB). What is FSD Pharma's stock symbol? FSD Pharma trades on the NASDAQ under the ticker symbol "HUGE." How do I buy shares of FSD Pharma? Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is FSD Pharma's stock price today? One share of HUGE stock can currently be purchased for approximately $1.21. How much money does FSD Pharma make? FSD Pharma (NASDAQ:HUGE) has a market capitalization of $47.26 million. The company earns $-23,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How can I contact FSD Pharma? FSD Pharma's mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The official website for the company is fsdpharma.com. The company can be reached via phone at (416) 854-8884 or via email at ir@fsdpharma.com. This page (NASDAQ:HUGE) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.